As CEO and Founder of Trialogics, Chris brings a wealth of technical expertise and clinical knowledge to the team. He understands that technology is a tool to help find a cure and different trials require different technology to succeed.
He founded Trialogics to solve the problem of outdated, inflexible eClinical software. He guided the development team in developing software that is customized to meet specific clinical trial needs.
John Moore has been Executive Chairman of Trialogics since inception. He has invested in energy, new materials, medical devices and biotech. In 2002, he co-founded Edson Moore Healthcare Ventures to acquire sixteen interests in biotech companies from Elan Pharmaceuticals for $148 million. He served as Chairman of ImaRx Therapeutics and Elite Pharmaceuticals as well as holding numerous other biotech company board positions. He believes the best new business idea is to solve the biggest headache of his last business. He is excited by Trialogics mission to help deliver faster cures through better systems.
Edoardo co-founded Top Quartile Partners (‘TQP’) in 2007. TQP’s focus is on direct investments. Edoardo’s portfolio includes investments in communication software, healthcare, luxury goods, funeral services and Saas. In 2012 he completed the buy-out of Groupe Roc Eclerc (a leading French funeral services company) together with French entrepreneur Daniel Abittan. Most recently, Edoardo completed an investment in Useed, a leader in providing crowd-funding solutions to higher education institutions and Trialogics.
Ann Strong joined Trialogics’ Scientific Advisory Board in April, 2016. Ann is the President and CEO of Select Clinical Trials and previously served as VP and Chief Administrative Officer for Schulman Associates IRB, where she served for 16 years. With more than 30 years of proven leadership and expertise in the clinical research industry, Ann is dedicated to ensuring the protection of human research subjects through delivering ethical, responsive and thoughtful service. Ann’s passions have been recognized through being named “Woman of Outstanding Leadership” and “Wyoming Citizen of the Year” and through serving as a volunteer for other causes that she is committed to.
Michael Longhi brings over 25 years of industry experience, including 20 years in clinical operations and study management. Mike is the Director of Project Management for Cleave Biosciences, Inc., where he has managed clinical operations and IND submissions, as well as providing project management and coordination for various pre-clinical stage projects. Prior to joining Cleave, Michael was a Senior Clinical Research Manager for Medtronic, Inc. from 2007-2012, where he led a clinical operations team and managed several clinical trials for a variety of product lines and spine disorders. Michael received his MS in Biology in 1990 and a BS in Biology, Cum Laude, in 1987, both from Wake Forest University.